Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-03446962 in advanced hepatocellular carcinoma
NCT01911273Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Oct 2013
- Primary completion
- Jul 2014
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of ascrinvacumab in hepatocellular carcinoma (HCC), sponsored by Pfizer. Primary endpoint: Overall Survival at 24 months. Started Oct 2013; status: terminated.
02
Drugs
ascrinvacumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01911273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01911273.